226 related articles for article (PubMed ID: 21735230)
21. Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system.
Nakamura K; Mizutani R; Sanbe A; Enosawa S; Kasahara M; Nakagawa A; Ejiri Y; Murayama N; Miyamoto Y; Torii T; Kusakawa S; Yamauchi J; Fukuda M; Yamazaki H; Tanoue A
J Biosci Bioeng; 2011 Jan; 111(1):78-84. PubMed ID: 20837398
[TBL] [Abstract][Full Text] [Related]
22. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
Gómez-Lechón MJ; Castell JV; Donato MT
Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
[TBL] [Abstract][Full Text] [Related]
23. Benzo[a]pyrene-induced elevation of GSH level protects against oxidative stress and enhances xenobiotic detoxification in human HepG2 cells.
Lin T; Yang MS
Toxicology; 2007 Jun; 235(1-2):1-10. PubMed ID: 17416446
[TBL] [Abstract][Full Text] [Related]
24. Regulation of the alpha-fetoprotein gene by the isoforms of ATBF1 transcription factor in human hepatoma.
Ninomiya T; Mihara K; Fushimi K; Hayashi Y; Hashimoto-Tamaoki T; Tamaoki T
Hepatology; 2002 Jan; 35(1):82-7. PubMed ID: 11786962
[TBL] [Abstract][Full Text] [Related]
25. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines.
Noda K; Miyoshi E; Gu J; Gao CX; Nakahara S; Kitada T; Honke K; Suzuki K; Yoshihara H; Yoshikawa K; Kawano K; Tonetti M; Kasahara A; Hori M; Hayashi N; Taniguchi N
Cancer Res; 2003 Oct; 63(19):6282-9. PubMed ID: 14559815
[TBL] [Abstract][Full Text] [Related]
26. Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver.
el Mouelhi M; Didolkar MS; Elias EG; Guengerich FP; Kauffman FC
Cancer Res; 1987 Jan; 47(2):460-6. PubMed ID: 3024821
[TBL] [Abstract][Full Text] [Related]
27. Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04.
Lim PL; Tan W; Latchoumycandane C; Mok WC; Khoo YM; Lee HS; Sattabongkot J; Beerheide W; Lim SG; Tan TM; Boelsterli UA
Toxicol In Vitro; 2007 Dec; 21(8):1390-401. PubMed ID: 17590308
[TBL] [Abstract][Full Text] [Related]
28. Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering.
Donato MT; Jover R; Gómez-Lechón MJ
Curr Drug Metab; 2013 Nov; 14(9):946-68. PubMed ID: 24160292
[TBL] [Abstract][Full Text] [Related]
29. Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells.
Mansuroglu T; Baumhoer D; Dudas J; Haller F; Cameron S; Lorf T; Füzesi L; Ramadori G
Eur J Gastroenterol Hepatol; 2009 Oct; 21(10):1206-11. PubMed ID: 19491699
[TBL] [Abstract][Full Text] [Related]
30. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models.
Donato MT; Castell JV; Gómez-Lechón MJ
J Hepatol; 1999 Sep; 31(3):542-9. PubMed ID: 10488716
[TBL] [Abstract][Full Text] [Related]
31. Establishment of rat precision-cut fibrotic liver slice technique and its application in verapamil metabolism.
Guo Y; Wang H; Zhang C
Clin Exp Pharmacol Physiol; 2007; 34(5-6):406-13. PubMed ID: 17439408
[TBL] [Abstract][Full Text] [Related]
32. Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells.
Westerink WM; Schoonen WG
Toxicol In Vitro; 2007 Dec; 21(8):1592-602. PubMed ID: 17716855
[TBL] [Abstract][Full Text] [Related]
33. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells.
Anthérieu S; Chesné C; Li R; Camus S; Lahoz A; Picazo L; Turpeinen M; Tolonen A; Uusitalo J; Guguen-Guillouzo C; Guillouzo A
Drug Metab Dispos; 2010 Mar; 38(3):516-25. PubMed ID: 20019244
[TBL] [Abstract][Full Text] [Related]
34. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.
Prueksaritanont T; Gorham LM; Hochman JH; Tran LO; Vyas KP
Drug Metab Dispos; 1996 Jun; 24(6):634-42. PubMed ID: 8781778
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
36. Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line.
Le Vee M; Jigorel E; Glaise D; Gripon P; Guguen-Guillouzo C; Fardel O
Eur J Pharm Sci; 2006 May; 28(1-2):109-17. PubMed ID: 16488578
[TBL] [Abstract][Full Text] [Related]
37. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
[TBL] [Abstract][Full Text] [Related]
38. Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium.
Lakehal F; Wendum D; Barbu V; Becquemont L; Poupon R; Balladur P; Hannoun L; Ballet F; Beaune PH; Housset C
Hepatology; 1999 Dec; 30(6):1498-506. PubMed ID: 10573530
[TBL] [Abstract][Full Text] [Related]
39. Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines.
Kvist AJ; Kanebratt KP; Walentinsson A; Palmgren H; O'Hara M; Björkbom A; Andersson LC; Ahlqvist M; Andersson TB
Biochem Pharmacol; 2018 Sep; 155():124-140. PubMed ID: 29953844
[TBL] [Abstract][Full Text] [Related]
40. Constitutive production of colony-stimulating factors by human hepatoma cell lines: possible correlation with cell differentiation.
Wang SY; Chen LY; Tsai TF; Su TS; Choo KB; Ho CK
Exp Hematol; 1996 Feb; 24(3):437-44. PubMed ID: 8599973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
